06-14 Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis CI
05-28 The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer CI
05-25 Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting CI
12-08 Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium CI
11-24 Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS CI
25-03-20 Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm CI
24-12-11 Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela CI
23-12-11 Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium CI
23-12-08 Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023 CI
23-11-20 The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU CI
23-10-30 Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group CI
23-09-20 European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation CI
23-05-25 The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study CI
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 65 2014-01-15
Compliance Officer - 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
6/10/20 Free

Chief Executive Officer

3,872,092 7.3739%
6/10/20 Tender

Executive/Senior Manager

250,891 0.4778%
6/10/20 Tender

Director

151,450 0.2884%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 570M
+0.17%+3.62%+70.94%+109.68% 73.25B
+1.73%+13.43%+57.10%+90.54% 61.95B
0.00%-2.89%+1.16%+492.45% 28.02B
+5.24%+5.33%+57.01%+17.77% 24.15B
+1.42%+0.17%-17.41%-15.77% 23.01B
-0.71%+5.26%+241.94%+427.03% 18.35B
0.00%+5.57%+39.57%-14.30% 19.46B
+3.83%+2.65%+25.00%+592.85% 15.92B
+1.34%+3.45%+40.62%+151.66% 12.96B
Average +1.32%+1.24%+57.33%+205.77% 30.79B
Weighted average by Cap. +1.25%+3.43%+57.30%+167.72%
Logo Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Employees
-